OrbiMed’s Crescent Biopharma CBIO Stock Holding History

OrbiMed’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,376	Closed	-$4.72M	–	136
2017 Q3	$4.72M	Hold	3,376	–	–	0.05%	124
2017 Q2	$3.77M	Buy	+3,376	New	+$2.79M	0.04%	122

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OrbiMed's CBIO Position: Q4 2017 in Review

OrbiMed sold out of Crescent Biopharma (CBIO) in Q4 2017, closing a stake of 3,376 shares — an estimated $4.72M sold.

OrbiMed first reported a position in CBIO in Q2 2017 and held it in 2 quarters. The position peaked at $4.72M in Q3 2017. 80 funds tracked by Wall St. Rank hold CBIO as of Q4 2017.

OrbiMed reported no remaining Crescent Biopharma position as of Q4 2017 after selling out during the quarter.
OrbiMed sold 3,376 Crescent Biopharma shares in Q4 2017, an estimated $4.72M.
OrbiMed first reported a position in Crescent Biopharma in Q2 2017 and held it in 2 quarters.
OrbiMed's Crescent Biopharma position peaked at $4.72M in Q3 2017.
80 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2017.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.